View Author
patient methylation glioblastoma temozolomide radiotherapy promoter survival trial treatment glioma mgmt promoter methylation cancer tumor status prognostic study analysis factor oncol phase model fication methylated outcome anaplastic group value expression chemotherapy gefitinib bene fit population tissue table sample mutation grade eortc response therapy mgmt methylation status probability adjuvant adjuvant temozolomide classi resection probe unmethylated signi research month effect classi fication methylation status performance status mgmt methylation van den neuropathol 1·00 review agent university 2 years marker mgmt status correlation surgery gbm-o prognostic factors association pathway figure identi idh 1 mutations alkylating dataset performance analyses number protein
7 Most Recent Publications
|
MGMT methylation analysis of glioblastoma on the Infinium methylation BeadChip identifies two distinct CpG regions associated with gene silencing and outcome, yielding a prediction model for comparisons across datasets, tumor grades, and CIMP-status
(Article)
Bady, P. Sciuscio, D. Mcdonald, D.R. Lacombe, D. Stupp, R. Delorenzi, M. Hegi, M.E. Diserens, A.C. Bloch, J. Bent, M.J. van den Marosi, C. Dietrich, P-Y. Weller, M. Mariani, L. Heppner, F.L. |
2012-10-01
|
|
Presence of an oligodendroglioma-like component in newly diagnosed glioblastoma identifies a pathogenetically heterogeneous subgroup and lacks prognostic value: central pathology review of the EORTC_26981/NCIC_CE.3 trial
(Article)
Hegi, M.E. Janzer, R.C. Hamou, M.F. Bady, P. Weller, M. Bent, M.J. van den Mason, W.P. Mirimanoff, R.O. Stupp, R. Mokhtari, K. Wesseling, P. Lambiv, W.L. Gorlia, T. Kouwenhoven, M.C.M. Hartmann, C. Deimling, A. von Martinet, D. Besuchet Schmutz, N. Diserens, A.C. |
2012-01-16
|
|
Pathway analysis of glioblastoma tissue after preoperative treatment with the EGFR tyrosine kinase inhibitor gefitinib - A phase II trial
(Article)
Hegi, M.E. Diserens, A.C. Heppner, F. Yonekawa, Y. Merlo, A. Frei, K. Mariani, L. Hofer, S. Bady, P. Kamoshima, Y. Kouwenhoven, M.C.M. Delorenzi, M. Lambiv, W.L. Hamou, M.F. Matter, M.S. Koch, A. |
2011-06-01
|
|
Molecular diagnostics of gliomas: The clinical perspective
(Article)
Tabatabai, G. Stupp, R. Bent, M.J. van den Hegi, M.E. Tonn, J.C. Wick, W. Weller, M. |
2010-11-01
|
|
MGMT promoter methylation in malignant gliomas: Ready for personalized medicine?
(Article)
Weller, M. Stupp, R. Reifenberger, G. Brandes, A. Bent, M.J. van den Wick, W. Hegi, M.E. |
2010-01-01
|
|
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial
(Article)
Stupp, R. Hegi, M.E. Hau, P. Brandes, A. Gijtenbeek, J. Marosi, C. Vecht, C.J. Mokhtari, K. Wesseling, P. Villa, S. Eisenhauer, E. Gorlia, T. Mason, W.P. Weller, M. Lacombe, D. Cairncross, J.G. Mirimanoff, R.O. Bent, M.J. van den Taphoorn, M.J. Janzer, R.C. Ludwin, S.K. Allgeier, A. Fisher, B. Belanger, K. |
2009-05-01
|
|
Nomograms for predicting survival of patients with newly diagnosed glioblastoma: prognostic factor analysis of EORTC and NCIC trial 26981-22981/CE.3
(Article)
Gorlia, T. Bent, M.J. van den Lacombe, D. Stupp, R. Hegi, M.E. Mirimanoff, R.O. Weller, M. Cairncross, J.G. Eisenhauer, E. Belanger, K. Brandes, A. Allgeier, A. |
2008-01-01
|
